FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051)
Status:
Completed
Trial end date:
2003-10-01
Target enrollment:
Participant gender:
Summary
This study was conducted among women who had previously received alendronate for 3 to 6 years
during the Fracture Intervention Trial (FIT). Participants in the FLEX study were randomly
assigned to receive alendronate (either 5 or 10 mg/day) or matching placebo during the next 5
years, in order to evaluate the effects of continuing or discontinuing alendronate treatment
on bone mineral density and biochemical markers of bone turnover.